Archive for October, 2010

2010 Mid-Atlantic Bio Conference Hosted a Stellar Lineup of Industry Luminary Speakers

Friday, October 29th, 2010

2010 Mid-Atlantic Bio Conference Hosted a Stellar Lineup of Industry Luminary Speakers

The 2010 Mid-Atlantic Bio today completed another successful conference hosting more than 700 registrants from 22 states and 4 countries, with more than 400 companies and 50 qualified investors participating. Dedicated to promoting the biotechnology industry in the Mid-Atlantic region, the conference is hosted collectively by the region’s most influential bioscience and investor associations, the Mid-Atlantic Venture Association (MAVA), the Tech Council of Maryland/MdBio (MdBio) and the Virginia Biotechnology Association (VaBIO).

The final day of the conference featured a joint plenary with the leaders of the Pharmaceutical
Research and Manufacturers of America (PhRMA) and Biotechnology Industry Organization (BIO). During this plenary session, John Castellani, president and CEO of PhRMA, and James Greenwood, president and CEO of BIO discussed the challenges posed by the disconnect in public understanding of the impact of the bioscience industry from a policy standpoint. Castellani stressed the urgency of addressing these issues by citing a recent public survey which indicated that the cost of treating Alzheimer’s in America would reach a trillion dollars by 2015. He also noted another national survey in which 57% of Americans rated IT as being more important than bioscience which was one indicator of the importance of education about the industry.
The event came to a close with a packed plenary session featuring John F. Crowley, chairman and CEO of Amicus Therapeutics. He shared his amazing story about the development of a treatment for Pompe disease after two of his children were diagnosed with the fatal neuromuscular disorder. The Crowley family’s journey to save their children is the inspiration for the 2010 major motion picture, “Extraordinary Measures”, starring Harrison Ford and Brendan Fraser. Crowley spoke on the heels of an announcement made earlier today that GlaxoSmithKline and Amicus Therapeutics entered an exclusive worldwide agreement to develop and commercialize Amigal™ for Fabry Disease, resulting in $170 m in potential milestone payments.

This year’s conference also featured individuals from 26 companies who were selected to present in the Showcase track, Emerging Growth track and a newly added First Look/Fast Pitch track. The companies chosen specialize in medical devices, health care IT, diagnostics, drug development, pharmaceuticals, biotherapeutics, biopharmaceuticals, therapeutics and gene therapeutics.

“This year’s conference was a particularly impactful event given the many luminary speakers, the strong connections that were made, and business that was conducted,” says Julia Spicer, executive director of the Mid-Atlantic Venture Association (MAVA). “This event was a great kick-off in preparation for the region hosting the 2011 BIO International Convention next year.”

“Given the challenging economic climate the past few years, we’re fortunate to have such a strong turnout for our event yet again this year. We were pleased to bring the community together in the Mid-Atlantic region and are also extremely thankful to our sponsors and exhibitors for their strong support of our event,” said Richard A. Zakour, PhD, executive director of The Tech Council of Maryland/MdBio.

ABOUT MID-ATLANTIC BIO
The Mid-Atlantic Bio Conference, scheduled October 27-29, 2010, in Bethesda, Maryland, is co-hosted by the Tech Council of Maryland/MdBio (TCM/MdBio), the Mid-Atlantic Venture Association (MAVA), and the Virginia Biotechnology Association (VaBIO). Mid-Atlantic Bio benefits from broad regional support from the investor and greater business communities, academic institutions, government agencies, and partnering regional associations. For more information, or to register or sponsor, please visit www.midatlanticbio.org.

2010 Mid-Atlantic Bio Conference Hosted a Stellar Lineup of Industry Luminary Speakers Press Release (Full .pdf version)

Mid-Atlantic Bio Welcomes Bio West Virginia and Women In Bio as New 2010 Partners

Wednesday, October 6th, 2010

Mid-Atlantic Bio Welcomes Bio West Virginia and Women In Bio as New 2010 Partners

For the first time, the Bioscience Association of West Virginia (BioWV) and Women In Bio (WIB) will partner with Mid-Atlantic Bio for the 2010 Mid-Atlantic Bio Conference
taking place October 27-29 at the North Bethesda Marriott Convention Center in Bethesda, Md.

As 2010 strategic partners, BioWV and WIB will join event hosts the Tech Council of Maryland/MdBio (TCM/MdBio), the Mid-Atlantic Venture Association (MAVA), and the Virginia Biotechnology Association (VaBIO) to create an even stronger platform for the combined communities of their industry constituents to come together at this year’s conference. Both BioWVA and WIB serve different segments of the expanding biotechnology industry, each important in the industry ecosystem. It is anticipated that both organizations will have strong representation from their respective membership groups at this year’s conference.

The Bioscience Association of West Virginia (BioWV) is that state’s official bioscience organization and is a part of the Council of State Bioscience Associations (CSBA). It serves West Virginia biotech companies with education and helps to increase public awareness of the biotechnology industry in the state.

Women in Bio (WIB) is a national organization dedicated to encouraging entrepreneurship and furthering the career development of women active in the life science industry. WIB is expanding nationally but has its
roots in the Maryland/DC/Virginia corridor.

“We are thrilled to continue building strong alliances with these organizations,” said Mid-Atlantic Venture Association (MAVA) Executive Director Julia Spicer. “We can’t think of two more fitting state and
national partners to welcome to this event, as each share the same deep commitment to bringing some of the best possible resources to their respective industry members and constituents.”

Now in its seventh year, Mid-Atlantic Bio is the only globally-focused, yet regionally-based, event to combine components of a bioscience industry convention with an investor conference under one roof. More
than 800 national and international industry leaders, government representatives, executives, researchers, investors, entrepreneurs, and professional services firms will gather to promote networking, business
expansion, and technical-knowledge sharing. Home to industry-critical regulatory and research agencies; federal policymaking; and business and scientific centers of excellence, the Mid-Atlantic is a unique center for
the global bioscience industry.

Unparalleled Plenary Speakers

The conference brings some of the world’s most noted scientists and executives together all under one roof to provide important access for conference attendees to global thought-leaders. This year’s event offers
a top tier line-up of plenary speakers, unique to this event, including:

  • John Castellani, President and CEO, PhRMA
  • John F. Crowley, JD, MBA, Chairman and CEO, Amicus Therapeutics
  • Frederick Frank, Vice Chairman, Peter J. Solomon Company
  • James Greenwood, President and CEO, BIO
  • Martine A. Rothblatt, PhD, JD, MBA, Chairman and CEO of United
    Therapeutics Corporation
  • Joshua M. Sharfstein, MD, Principal Deputy Commissioner, U.S. Food
    and Drug Administration
  • H. Thomas Watkins, President and CEO, Human Genome Sciences


Valued Timely and Topical Conference Sessions:

Designed as a platform that brings together science, company builders, commercial interests and collaborators, capital sources, and federal and regulatory thought-leaders, the
2010 program
includes a variety of important industry topics—ranging from the latest in policy and regulatory matters, business and financing opportunities, and CEO War Stories to advances in science and technology—and showcases exciting companies from the biosciences field. A few of the highlighted sessions include:

  • Building a Workforce Culture Around Commercialization
  • Corporate Venture and Early Stage Partnerships
  • New Science Technologies: Regional Successes
  • Drugs and Devices: Reimbursement in a Post-Healthcare Reform World
  • Capital Eco-Systems: Formation and International Markets
  • An Insider’s View on Washington
  • Synthetic Biology – Applications and Implications
  • Accessing the Regulatory Risk: Your Path to Approval
  • CEO War Stories: A Roundtable


Attendees Get a Close Look at the Latest Companies to Watch

Each year at Mid-Atlantic Bio, a select group of life science companies are chosen to present their respective stories before conference attendees, which include an audience of capital sources, including
corporate business development professionals, peer scientists and company leaders, venture capitalists, angel investors, and various other qualified financing sources along with important industry
professionals and potential strategic partners.


BioMatch:

Mid-Atlantic Bio’s signature networking program, BioMatch, is designed specifically for the life sciences and biotech industries, and provides registered attendees access to advanced partnering software that
facilitates personalized, one-on-one meetings between the leading bioscience organizations and industry leaders.


Partial List of Conference Sponsors:

MD Biotechnology Center, MedImmune, Biotechnology Industry Organization, BioMed Realty Trust, Inc., BDO, Alexandria Real Estate Equities, Inc., Janelia Farms Research Campus of Howard Hughes Medical Institute, NIH
Federal Credit Union, George Mason University, Virginia Tech, James Madison University, Broad Oak Partners, H.I.G. BioVentures, CIT Gap Funds, Intersouth Partners, New Enterprises Associates, Oxford Finance,
TEDCO, Third Security, LLC


ABOUT MID-ATLANTIC BIO

The Mid-Atlantic Bio Conference, scheduled October 27-29, 2010, in Bethesda, Maryland, is co-hosted by the Tech Council of Maryland/MdBio (TCM/MdBio), the Mid-Atlantic Venture Association (MAVA), and the
Virginia Biotechnology Association (VaBIO). Mid-Atlantic Bio benefits from broad regional support from the investor and greater business communities, academic institutions, government agencies, and partnering
regional associations. For more information, or to register or sponsor, please visit
www.midatlanticbio.org.

# # #

Mid-Atlantic Bio Welcomes Bio West Virginia and Women In Bio Press Release (Full .pdf version)

PhRMA and BIO Leaders to Jointly Address Mid-Atlantic Bio Conference

Monday, October 4th, 2010

PhRMA and BIO Leaders to Jointly Address Mid-Atlantic Bio Conference

Mid-Atlantic Bio today announced that John J. Castellani, the new President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) and James Greenwood, the President and CEO of the Biotechnology Industry Organization (BIO) will share the stage and address attendees in a joint plenary session at 2010 Mid-Atlantic Bio Conference, on October 29 at the North Bethesda Marriott Convention Center in Bethesda, Md.

As president and CEO of PhRMA, Castellani leads the association’s mission of effectively advocating for public policies that foster the discovery of life-saving and life-enhancing new medicines for patients by America’s biopharmaceutical companies. PhRMA represents the country’s leading pharmaceutical and biotechnology research companies, which are devoted to developing medicines that allow patients to live longer, healthier and more productive lives.

James Greenwood leads the advocacy efforts for BIO in shaping public policy on a variety of fronts critical to the success of the biotechnology industry at the state and national levels as well as internationally. BIO has more than 1,100 members that are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products across the United States and in more than 30 other nations.

“We are very privileged to have both the BIO and PhRMA leaders join us at our event and address the attendees,” said Virginia Biotechnology Association Executive Director, Mark A. Herzog. “With these organizations representing the nation’s leading pharmaceutical research and biotech companies, it is important to have such strong advocates for our industry speaking at the event. With adding these two leaders to our plenary session line-up, we truly have a program that is unrivaled and demonstrates the Mid-Atlantic region’s access and power in this industry.”

Castellani and Greenwood join the already impressive list of plenary speakers for Mid-Atlantic Bio, including John F. Crowley, JD, MBA, Chairman and CEO, Amicus Therapeutics; Frederick Frank, Vice Chairman, Peter J. Solomon Company; Martine A. Rothblatt, PhD, JD, MBA, Chairman and CEO of United Therapeutics Corporation; Joshua M. Sharfstein, M.D., Principal Deputy Commissioner, U.S. Food and Drug Administration and H. Thomas Watkins, President and CEO, Human Genome Sciences.

Now in its sixth year, Mid-Atlantic Bio is the only globally-focused, yet regionally-based, event to combine components of a bioscience industry convention with an investor conference under one roof. More than 800 national and international industry leaders, government representatives, executives, industry and academic researchers, investors, entrepreneurs, and professional services firms will gather to promote networking, business expansion, and technical-knowledge sharing. Home to industry-critical regulatory and research agencies; federal policymaking; and business and scientific centers of excellence, the Mid-Atlantic is a unique center for the global bioscience industry.

Conference Sessions:
Designed to be a platform that brings together science, company builders, commercial interests
and collaborators, capital sources, and federal and regulatory thought-leaders, the 2010 program includes a variety of important industry topics—ranging from the latest in policy and regulatory matters, business and financing opportunities, and CEO War Stories to advances in science and technology—and showcases exciting companies from the biosciences field. A few of the highlighted sessions include:

  • Building a Workforce Culture Around Commercialization
  • Corporate Venture and Early Stage Partnerships
  • New Science Technologies: Regional Successes
  • Drugs and Devices: Reimbursement in a Post-Healthcare Reform World
  • Capital Eco-Systems: Formation and International Markets
  • An Insider’s View on Washington
  • Synthetic Biology – Applications and Implications
  • Accessing the Regulatory Risk: Your Path to Approval
  • CEO War Stories: A Roundtable

Company Presentations:
Each year at Mid-Atlantic Bio, a number of life science companies are chosen to present before an audience of capital sources, including corporate business development professionals, peer scientists and company leaders, venture capitalists, angel investors, and various other qualified financing sources along with important industry professionals and potential strategic partners.

BioMatch:
Mid-Atlantic Bio’s signature networking program, BioMatch is designed specifically for the life sciences and biotech industries, and provides registered attendees access to advanced partnering software that facilitates personalized, one-on-one meetings between the leading bioscience organizations and industry leaders.

Partial List of Conference Sponsors:
MD Biotechnology Center, MedImmune, Biotechnology Industry Organization, BioMed Realty Trust, Inc., BDO, Alexandria Real Estate Equities, Inc., Janelia Farms Research Campus of Howard Hughes Medical Institute, NIH Federal Credit Union, George Mason University, Virginia Tech, James Madison University, Broad Oak Partners, H.I.G. BioVentures, CIT Gap Funds, Intersouth Partners, New Enterprises Associates, Oxford Finance, TEDCO, Third Security, LLC

ABOUT MID-ATLANTIC BIO
The Mid-Atlantic Bio Conference, scheduled October 27-29, 2010, in Bethesda, Maryland, is co-hosted by the Tech Council of Maryland (TCM),  the Mid-Atlantic Venture Association (MAVA), and the Virginia Biotechnology Association (VaBIO). Mid-Atlantic Bio benefits from broad regional support from the investor and greater business communities, academic institutions, government agencies, and partnering regional associations. For more information, or to register or sponsor, please visit www.midatlanticbio.org.

PhRMA-BIO Press Release  (Full .pdf version)